This site is intended for U.S. Healthcare Professionals.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Request a Rep

ONUREG® is incorporated into both DNA and RNA where it exerts multiple antileukemic effects ONUREG® is incorporated into both DNA and RNA where it exerts multiple antileukemic effects

Pharmacodynamic profile for ONUREG®1

Recommended dosing for ONUREG® Recommended dosing for ONUREG®